Company: ABUS
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012305
Chunk: 20

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 20
---
. Mr. Hasija is an accomplished healthcare executive with over 20 years of strategic and operational experience. Mr. Hasija has served as President and Founder of Double Filtered, a healthcare strategy consultancy, since 2024. In his role as President, Mr. Hasija designed growth strategies, prepared organizations for successful product launches, and advised executives and entrepreneurs on how to scale their businesses. Previously, Mr. Hasija served as Vice President, Sales and Marketing, Cardiovascular and Metabolic Diseases at Johnson & Johnson in 2023 and served in various roles at Novartis, including Vice President, Oncology Global Marketing, from 2009 to 2023. Prior to Novartis, Mr. Hasija worked as a strategy consultant at McKinsey from 2005 to 2009 and in vaccines manufacturing at Merck & Co. from 2000 to 2004. Mr. Hasija earned his B.S. in Chemical Engineering and M.S. in Chemical Engineering from the University of Michigan, and his M.B.A. from the University of Chicago Booth School of Business. Our Board believes Mr. Hasija’s experiences in the healthcare industry qualifies him to serve on our Board. Mr. Hasija was recommended to our Board by a shareholder. The following are brief biographies of our current executive officers: Lindsay Androski, JD, MBA, CFA, President & Chief Executive Officer, and Chairperson of the Board. Please refer to the immediately preceding section for Ms. Androski’s biographical information. 11 TABLE OF CONTENTS Tuan Nguyen, Chief Financial Officer. Mr. Nguyen has almost two decades of experience in biopharma working on small molecules and AAV gene therapies. Most recently, from March 2022 to March 2025, he served as Chief Financial Officer of Kinevant Sciences, a clinical-stage biopharmaceutical company dedicated to treating rare inflammatory and autoimmune diseases. Prior to this, from May 2020 to March 2022, he was Vice President of Finance at Adverum Biotechnologies, a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. Prior to that he held various senior finance leadership roles at Intarcia Therapeutics, FibroGen, and UCB. He has helped raise over $2 billion in dilutive and non dilutive capital. Mr. Nguyen earned his MBA with dual concentration in Finance and Entrepreneurship, Innovation, & Change from Emory University. Arrangements